Gemcitabine, fluorouracil, mitomycin C, 5% carbon dioxide/oxygen medical gas mixture, nicotinamide clinical trials

A randomised Phase III trial to assess whether radiotherapy with radiosensitisers is beneficial in patients with high-risk non-muscle invasive bladder cancer when compared with the standard of care treatment, Bacillus Calmette-Guerin

This study compares two treatments for high-risk bladder cancer that hasn't spread to the muscle: standard treatment (BCG immunotherapy) versus a new approach combining radiotherapy with special drugs. We want to see if the new approach works better to prevent cancer recurrence or progression.